FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022245596> ?p ?o ?g. }

• W2022245596 endingPage "201" @default.
• W2022245596 startingPage "195" @default.
• W2022245596 abstract "In this phase I/II clinical trial the antitumor activity of high-dose tamoxifen when administered in combination with vinblastine was assessed and the toxicity profile of this combination characterized. All 25 patients enrolled in this study were required to have androgen-independent prostate cancer and to maintain androgen ablation during treatment. Vinblastine was given by continuous infusion over 5 days. Doses were increased from 0.9 mg/m2/day to 1.5 mg/m2/day in successive cohorts of at least 3 patients, with no further escalation even in the absence of dose-limiting toxicity. Intra-patient dose escalation was permitted. Tamoxifen was administered at a dose of 200 mg/kg on day 1, then 120 mg/kg/day on day 2. Standard response criteria were utilized to assess antitumor activity and CTC toxicity criteria were used. Quality of life (QOL) pain assessments were evaluated at each visit to the clinic. Most patients tolerated the highest dose of vinblastine at 1.5 mg/m2/day by continuous infusion over 5 days with 200 mg/kg/day of tamoxifen on day 1 and day 2. One patient had a greater than 50% decline in prostate-specific antigen that lasted for 170 days. Two patients received dose reductions because of toxicity. The most common serious toxicities included neutropenia, and fatigue. Reversible neurosensory, neuromotor, neurocortical and neurocerebellar toxicities were reported. Six of the 25 patients enrolled in the study (24%) experienced reversible neurologic toxicity of at least grade III. No statistically significant differences between precycle assessment of QOL and subsequent cycles were observed. It is concluded that vinblastine at 1.5 mg/m2/day continuous i.v. infusion combined with tamoxifen 200 mg/kg/day on day 1 and day 2 is inactive, and not without toxicity in the treatment of advanced metastatic androgen-independent prostate cancer." @default.
• W2022245596 created "2016-06-24" @default.
• W2022245596 creator A5001321994 @default.
• W2022245596 creator A5003770647 @default.
• W2022245596 creator A5023730854 @default.
• W2022245596 creator A5027334479 @default.
• W2022245596 creator A5027488924 @default.
• W2022245596 creator A5032977250 @default.
• W2022245596 creator A5036730232 @default.
• W2022245596 creator A5044239219 @default.
• W2022245596 creator A5063126623 @default.
• W2022245596 creator A5063953417 @default.
• W2022245596 creator A5069928863 @default.
• W2022245596 creator A5091588790 @default.
• W2022245596 date "2003-01-01" @default.
• W2022245596 modified "2023-09-27" @default.
• W2022245596 title "A Phase I/II Study of High-Dose Tamoxifen in Combination with Vinblastine in Patients with Androgen-Independent Prostate Cancer" @default.
• W2022245596 cites W1662546471 @default.
• W2022245596 cites W1971208549 @default.
• W2022245596 cites W2023873685 @default.
• W2022245596 cites W2039363720 @default.
• W2022245596 cites W2044573147 @default.
• W2022245596 cites W2062178963 @default.
• W2022245596 cites W2103031848 @default.
• W2022245596 cites W2137267834 @default.
• W2022245596 cites W2165629556 @default.
• W2022245596 cites W2177330869 @default.
• W2022245596 cites W2317493108 @default.
• W2022245596 doi "https://doi.org/10.1080/02841860310010718" @default.
• W2022245596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12852695" @default.
• W2022245596 hasPublicationYear "2003" @default.
• W2022245596 type Work @default.
• W2022245596 sameAs 2022245596 @default.
• W2022245596 citedByCount "15" @default.
• W2022245596 countsByYear W20222455962013 @default.
• W2022245596 countsByYear W20222455962014 @default.
• W2022245596 countsByYear W20222455962015 @default.
• W2022245596 countsByYear W20222455962016 @default.
• W2022245596 countsByYear W20222455962018 @default.
• W2022245596 countsByYear W20222455962020 @default.
• W2022245596 countsByYear W20222455962021 @default.
• W2022245596 countsByYear W20222455962023 @default.
• W2022245596 crossrefType "journal-article" @default.
• W2022245596 hasAuthorship W2022245596A5001321994 @default.
• W2022245596 hasAuthorship W2022245596A5003770647 @default.
• W2022245596 hasAuthorship W2022245596A5023730854 @default.
• W2022245596 hasAuthorship W2022245596A5027334479 @default.
• W2022245596 hasAuthorship W2022245596A5027488924 @default.
• W2022245596 hasAuthorship W2022245596A5032977250 @default.
• W2022245596 hasAuthorship W2022245596A5036730232 @default.
• W2022245596 hasAuthorship W2022245596A5044239219 @default.
• W2022245596 hasAuthorship W2022245596A5063126623 @default.
• W2022245596 hasAuthorship W2022245596A5063953417 @default.
• W2022245596 hasAuthorship W2022245596A5069928863 @default.
• W2022245596 hasAuthorship W2022245596A5091588790 @default.
• W2022245596 hasBestOaLocation W20222455961 @default.
• W2022245596 hasConcept C121608353 @default.
• W2022245596 hasConcept C126322002 @default.
• W2022245596 hasConcept C126894567 @default.
• W2022245596 hasConcept C2776694085 @default.
• W2022245596 hasConcept C2777063308 @default.
• W2022245596 hasConcept C2777132456 @default.
• W2022245596 hasConcept C2777176818 @default.
• W2022245596 hasConcept C2780192828 @default.
• W2022245596 hasConcept C29730261 @default.
• W2022245596 hasConcept C530470458 @default.
• W2022245596 hasConcept C71924100 @default.
• W2022245596 hasConcept C90924648 @default.
• W2022245596 hasConceptScore W2022245596C121608353 @default.
• W2022245596 hasConceptScore W2022245596C126322002 @default.
• W2022245596 hasConceptScore W2022245596C126894567 @default.
• W2022245596 hasConceptScore W2022245596C2776694085 @default.
• W2022245596 hasConceptScore W2022245596C2777063308 @default.
• W2022245596 hasConceptScore W2022245596C2777132456 @default.
• W2022245596 hasConceptScore W2022245596C2777176818 @default.
• W2022245596 hasConceptScore W2022245596C2780192828 @default.
• W2022245596 hasConceptScore W2022245596C29730261 @default.
• W2022245596 hasConceptScore W2022245596C530470458 @default.
• W2022245596 hasConceptScore W2022245596C71924100 @default.
• W2022245596 hasConceptScore W2022245596C90924648 @default.
• W2022245596 hasIssue "3" @default.
• W2022245596 hasLocation W20222455961 @default.
• W2022245596 hasLocation W20222455962 @default.
• W2022245596 hasOpenAccess W2022245596 @default.
• W2022245596 hasPrimaryLocation W20222455961 @default.
• W2022245596 hasRelatedWork W1522696994 @default.
• W2022245596 hasRelatedWork W1967128516 @default.
• W2022245596 hasRelatedWork W1972823928 @default.
• W2022245596 hasRelatedWork W2011245851 @default.
• W2022245596 hasRelatedWork W2118863363 @default.
• W2022245596 hasRelatedWork W2338649218 @default.
• W2022245596 hasRelatedWork W2392413698 @default.
• W2022245596 hasRelatedWork W2418393430 @default.
• W2022245596 hasRelatedWork W2948359515 @default.
• W2022245596 hasRelatedWork W4248187291 @default.
• W2022245596 hasVolume "42" @default.
• W2022245596 isParatext "false" @default.
• W2022245596 isRetracted "false" @default.

• next